Brief: Genetron Health Enters Exclusive Global Licensing Agreement With Immuquad Biotechnologies To Develop And Commercialize Minimal Residual Disease Assays In Hematologic Cancer
22/10/2020 11:09
Oct 22 (Reuters) - Genetron Holdings Ltd GTH.O :
* GENETRON HEALTH ENTERS EXCLUSIVE GLOBAL LICENSING
AGREEMENT WITH
IMMUQUAD BIOTECHNOLOGIES TO DEVELOP AND COMMERCIALIZE MINIMAL
RESIDUAL DISEASE ASSAYS IN HEMATOLOGIC CANCER
* GENETRON HEALTH - EXCLUSIVE RIGHTS TO DEVELOP,
COMMERCIALIZE MRD
DETECTION PRODUCTS OR TESTING METHODS IN SELECT CANCERS USING
IMMUQUAD'S SEQ-MRD
* GENETRON HEALTH - HAS MADE A MINORITY EQUITY INVESTMENT IN
IMMUQUAD
Source text for Eikon: ID:nGNX89QYMJ
Further company coverage: GTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genetron Holdings
See all newsBrief: Genetron Holdings Requested That Trading Of Its ADSs On Nasdaq Be Suspended As Of Close Of Trading On March 28, 2024
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
Genetron surges on $126 mln deal to go private